Wall Street Zen lowered shares of Immutep (NASDAQ:IMMP - Free Report) from a hold rating to a sell rating in a research note published on Friday morning.
Immutep Stock Down 0.3%
Shares of NASDAQ IMMP traded down $0.01 during mid-day trading on Friday, hitting $1.86. The stock had a trading volume of 113,532 shares, compared to its average volume of 217,222. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.25 and a quick ratio of 18.25. The company has a 50 day moving average of $1.75 and a two-hundred day moving average of $1.89. Immutep has a twelve month low of $1.32 and a twelve month high of $2.86.
Hedge Funds Weigh In On Immutep
Several hedge funds have recently made changes to their positions in the company. Jane Street Group LLC increased its position in shares of Immutep by 14.7% in the 1st quarter. Jane Street Group LLC now owns 51,574 shares of the biotechnology company's stock valued at $91,000 after acquiring an additional 6,617 shares during the period. OLD Mission Capital LLC acquired a new position in shares of Immutep in the 4th quarter valued at $36,000. Two Sigma Securities LLC acquired a new position in shares of Immutep in the 4th quarter valued at $74,000. XY Capital Ltd grew its position in Immutep by 52.0% during the 4th quarter. XY Capital Ltd now owns 164,655 shares of the biotechnology company's stock worth $357,000 after purchasing an additional 56,306 shares during the period. Finally, ABC Arbitrage SA purchased a new position in shares of Immutep during the 4th quarter valued at about $152,000. 2.32% of the stock is owned by institutional investors and hedge funds.
About Immutep
(
Get Free Report)
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Featured Stories
Before you consider Prima BioMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prima BioMed wasn't on the list.
While Prima BioMed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
